New VC fund to set sights on Israeli tech for eye diseases
Dr. Barak Azmon, an ophthalmologist and serial entrepreneur, is convinced Israel can become a 'meaningful player' in vision-related developments By SHOSHANNA SOLOMON| April 2018, 12:31 pm | Times of Israel Dr. Barak Azmon, an ophthalmologist [...]
MIXiii-Biomed 2018 – Registration and program online
MIXiii-Biomed 2018 – Registration and program online MIXiii-Biomed 2018 is fast approaching. This prestigious conference and exhibition is once again ready to launch start-ups into the international arena and to help thousands of delegates [...]
Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization
Dr. Arie Belldegrun, formerly Kite Pharma’s CEO, and Executive Chairman of Allogene Therapeutics, will be delivering the opening plenary talk at MIXiii-BIOMED conference, May 15-17, Tel Aviv. by john carroll — on April 3, 2018 08:00 AM EDT You need [...]
MIXiii-BIOMED 2018: Introducing the Best of Israel’s Life Science Innovations
Israel's 17th national life science and technology week to be held on May 15-17, 2018 at the David InterContinental Hotel in Tel Aviv NEWS PROVIDED BY MIXiii-BIOMED 07:30 ET | TEL AVIV, Israel, April 3, 2018 /PRNewswire/ The 17th annual MIXiii-BIOMED [...]
MedImmune to Develop Compugen Immuno-Oncology Antibodies
April 2, 2018 | GEN News Highlights AstraZeneca’s #MedImmune subsidiary has agreed to exclusively license and develop #bispecific and multispecific #immuno-oncology antibody products from Compugen’s pipeline, through a collaboration that #Compugen said today could generate for it [...]
InSight #Biopharmaceuticals Buys #Cancer #Treatment Company CureTech
As part of the deal, InSight commits to help develop CureTech’s lead product, which is currently in advanced #clinical trials Lilach Baumer17:4228.03.18 Pharmaceutical company InSight Biopharmaceuticals Ltd. has signed a deal to acquire cancer [...]